claim: ema endorses use of dexamethasone in covid-19 patients on oxygen or mechanical ventilation
evidence_1: dexamethasone was first considered a potential treatment for covid-19 because of its ability to reduce inflammation, which plays an important role in the disease process in some patients who have been admitted to hospital with covid-19.", "in patients receiving oxygen without mechanical ventilation, the figures were 23% with dexamethasone and 26% with usual care, with a relative reduction of about 20%.", "dexamethasone can be taken by mouth or given as an injection or infusion (drip) into a vein.", 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  "based on the review of available data, ema is endorsing the use of dexamethasone in adults and adolescents (from 12 years of age and weighing at least 40 kg) who require supplemental oxygen therapy.", "the chmps scientific opinion can be taken into account by eu member states and ema when evaluating dexamethasone medicines for the treatment of covid-19.")